Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: Targets for therapy

Biochemical Pharmacology

Volumn 53, Issue 11, 1997, Pages 1673-1682

  Dong, Ying ^c   Berners Price, Susan J ^c   Thorburn, David R ^a   Antalis, Toni ^b   Dickinson, Joanne ^b   Hurst, Terry ^c   Qiu, Ling ^b   Khoo, Soo Keat ^c   Parsons, Peter G ^b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c NONE

Author keywords

Cisplatin resistance; Mitochondria; Ovarian cancer; Platinum accumulation; Type 2 plasminogen activator inhibitor

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; ANTIMYCIN A1; AURANOFIN; CELL PROTEIN; CHLORAMPHENICOL; CISPLATIN; CITRATE SYNTHASE; CYTOCHROME C OXIDASE; DEQUALINIUM; DNA; DOXORUBICIN; ETHIDIUM BROMIDE; ETOPOSIDE; GLUTATHIONE; GOLD BIS[1,2 BIS(DIPHENYLPHOSPHINO)ETHANE] CHLORIDE; PHOSPHINE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLATINUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RHODAMINE 123; ROTENONE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SUCCINATE DEHYDROGENASE; TETRAPHENYLPHOSPHONIUM; TETRAZOLIUM; THENOYLTRIFLUOROACETONE; TRIPHENYLTETRAZOLIUM; UNINDEXED DRUG;

ARTICLE; CELL SURVIVAL; DRUG RESISTANCE; DRUG SENSITIVITY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MITOCHONDRION; OVARY CANCER; PRIORITY JOURNAL; RESPIRATORY CHAIN; TUMOR CELL LINE; UTERINE CERVIX CANCER;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA, NEOPLASM; DRUG RESISTANCE; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; GLUTATHIONE; HUMANS; MITOCHONDRIA; MULTIENZYME COMPLEXES; NAD(P)H DEHYDROGENASE (QUINONE); OXIDOREDUCTASES; PLATINUM; SERINE PROTEINASE INHIBITORS; SUCCINATE DEHYDROGENASE; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0030787561     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00015-4     Document Type: Article

References (58)

1. Andrews PA, Velury S, Mann SC and Howell SB, cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48: 68-73, 1988.
2. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki SI and Saijo N, Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer lines: Relation to DNA damage and repair. Cancer Res 50: 2549-2553, 1990.
3. Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD and Frei E III, Characterization of a human squamous carcinoma cell line resistant to cis-Diamminedichloroplatinum-II. Cancer Res 47: 388-393, 1987.
4. Godwin AK, Meister A, O'Dwyer PJ, Chin Shiou Huang, Hamilton TC and Anderson ME, High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
5. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF and Hamilton TC, Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53: 5225-5232, 1993.
6. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS, Overexpression of metallothionein confers resistance to anti-cancer drugs. Science (Wash. DC) 241: 1813-1815, 1988.
7. Kelly SL and Rozencweig M, Resistance to platinum compounds: Mechanisms and beyond. Eur J Clin Oncol 25: 1135-1140, 1989.
8. Andrews PA and Howell SB, Cellular pharmacology of cisplatin: Perspective on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990.
9. +-Adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 51: 3677-3681, 1991.
10. Gately DP and Howell SB, Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67: 1171-1176, 1993.
11. Andrews PA and Albright KD, Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 52: 1895-1901, 1992.
12. Moorehead RA, Armstrong SG, Wilson BC and Singh G, Cross-resistance to cisplatin in cells resistant to photofrinmediated photodynamic therapy. Cancer Res 54: 2556-2559, 1994.
13. 2: Evidence for mitochondrial involvement. Cancer Res 54: 1497-1502, 1994.
14. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A and Frie E III, Alkylating agents: In vitro studies of cross-resistance pattens in human tumor cell lines. Cancer Res 46: 4379-4383, 1986.
15. Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe DW, Brann TW, Worbut TT and Frei E III, Characteristics of five human cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47: 252-260, 1991.
16. Zindewich-Peotti K and Andrews PA, Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for Rhodamine 123 resistance. Cancer Res 52: 1902-1906, 1992.
17. Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung C-M, Mong S, Sadler PJ and Crooke ST, In vivo antitumor activity and in vitro cytotoxic properties of Bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res 46: 5486-5493, 1986.
18. Hoke GD, McCabe FL, Faucette LF, Bartus JO, Sung C, Jensen BD, Heys JR, Rush GF, Alberts DW, Johnson RK and Mirabell CK, In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to Bis(diphenylphosphine)ethane. Mol Pharmacol 39: 90-97, 1990.
19. Hoke GD, Rush GF, Bossard GF, Mcardle JV, Jensen BD and Mirabilli CK, Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines. J Biol Chem 263: 11203-11210, 1988.
20. Rush GF, Smith T, Hoke GD, Alberts DW, Snyder RM and Mirabelli CK, The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. II. Triethylphosphine gold chloride-induced alterations in mitochondrial function. Toxicol Appl Pharmacol 90: 391-400, 1987.
21. Davis S, Weiss MJ, Wong JR, Lampidis TJ and Chen LB, Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 260: 13844-13850, 1985.
22. Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD and Chen LB, Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci USA 84: 5444-5448, 1987.
23. Lichtshtein D, Kaback HR and Blume AJ, Use of a lipophilic cation for determination of membrane potential in neuroblastoma-glioma hybrid cell suspensions. Proc Natl Acad Sci USA 76: 650-654, 1979.
24. Ramsay RR and Singer TP, Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261: 7585-7587, 1986.
25. Hasman M, Valet G, Tapiero H, Trevorrow K and Lampidis T, Membrane potential difference between Adriamycin-sensitive and -resistant cells as measured by flow cytometry. Biochem Pharmacol 38: 305-312, 1989.
26. Mai MS and Allison WS, Inhibition of an oligomycin-sensitive ATPase by cationic dyes, some of which are atypical uncouplers of intact mitochondria. Arch Biochem Biophys 221: 467-476, 1983.
27. Nicklas WJ, Vyas I and Heikkila RE, Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508, 1985.
28. Wiseman A and Attardi G, Reversible tenfold reduction in mitochondrial DNA content of human cells treated with ethidium bromide. Mol Gen Genet 167: 51-67, 1978.
29. Desjardins P, Frost E and Morais R, Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol Cell Biol 5: 1163-1169, 1985.
30. Spolsky CM and Eisentstadt JM, Chloramphenicol-resistant mutants of human HeLa cells. FEBS Lett 25: 319-324, 1972.
31. Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G and Fiers W, Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO 12: 3095-3104, 1993.
32. Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K and Crooke ST, Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res 45: 32-39, 1985.
33. Snyder RM, Mirabelli CK and Crooke ST, Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem Pharmacol 35: 923-932, 1986.
34. Bernal SD, Lampidis TJ, Summerhayes IC and Chen LB, Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science (Wash. DC) 218: 1117-1119, 1982.
35. Bernal SD, Lampidis TJ, McIsaac RM and Chen LB, Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science (Wash. DC) 222: 169-172, 1983.
36. Wong JR and Chen LB, Recent advances in the study of mitochondria in living cells. Adv Cell Biol 2: 263-290, 1988.
37. Rideout DG, Calogeropooulou T, Jaworski JS, Dagnino R Jr and McCarthy MR, Phosphonium salts exhibiting selective anticarcinoma activity in vitro. Anticancer Drug Design 4: 465-480, 1989.
38. Bertoncello I, Bradley TR, Webber LM, Hodgson GS and Cambell JJ, Human tumor cell lines established using clonal agar culture. Aust J Exp Biol Med Sci 63: 241-248, 1985.
39. Ward B, Wallace K, Shephard JH and Balkwill FB, Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res 47: 2662-2667, 1987.
40. Van Haaften-Day C, Russel P, Wills EJ and Tattersall MHN, Flow cytometric and morphological studies of ovarian carcinoma cell lines and xenografts. Cancer Res 43: 3725-3731, 1983.
41. Dickinson JL, Bates EJ, Ferrante A and Antalis TM, Plasminogen activator inhibitor-type 2 inhibits TNFα-induced apoptosis: Evidence for a N alternate biological function. J Biol Chem 270: 27894-27904, 1995.
42. Chen TR, In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255-262, 1977.
43. Parsons PG and Morrison LE, DNA damage and selective toxicity of dopa and ascorbate: Copper in human melanoma cells. Cancer Res 42: 3783-3788, 1982.
44. Hissin PJ and Hilf RA, Fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74: 227-241, 1976.
45. Ahmann FR, Garewal HS, Schifman R, Celniker A and Rodney S, Intramolecular adenosine triphosphate as a measure of human tumor cell viability and drug modulated growth. In Vitro 23: 474-480, 1987.
46. Miller SA, Dykes DD and Polesky HF, A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215, 1988.
47. McKay K, New techniques in the pharmacokinetic analysis of cancer drugs II: The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry. Cancer Surveys 17: 407-415, 1993.
48. Lowerson SA, Taylor L, Briggs HL and Turnbull DM, Measurement of the activity of individual respiratory chain complexes in isolated fibroblast mitochondria. Anal Biochem 205: 372-374, 1992.
49. Zheng X, Shoffner JM, Voljavec AS and Wallace DC, Evaluation of procedures for assaying oxidative phosphorylation enzyme activities in mitochondrial myopathy muscle biopsies. Biochem Biophys Acta 1019: 1-10, 1990.
50. Bindoff LA, Desnuelle C, Birch-Machin MA, Pellisier JP, Serratrice G, Dravet C, Bureau M, Howell N and Turnbull DM, Multiple defects of the mitochondrial respiratory chain in a mitochondrial encephalopathy (MERRF) - a clinical, biochemical and molecular study. J Neural Sci 102: 17-24, 1991.
51. Chrertien D, Bourgeron T, Rotig A, Munnich A and Rustin P, The measurement of the rotenone-sensitive NADH cytochrome c reductase activity in mitochondria isolated from minute amount of human skeletal muscle. Biochem Biophys Res Commun 173: 26-33, 1990.
52. Rahman S, Blok RB, Dahl HHM, Danks DM, Kirby DM, Chow CW, Christodoulou J and Thouburn DR, Leigh syndrome: Clinical features and biochemical and DNA abnormalities. Ann Neurol 39: 343-351, 1996.
53. Musser DA and Oseroff AR, The use of tetrazolium salts to determine sites of damage to the mitochondrial electron transport chain in intact cells following in vitro photodynamic therapy with photofrin II. Photochem Photobiol 59: 621-626, 1994.
54. Mosmann T, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
55. Parsons PG, Lean J, Kable EPW, Favier D, Khoo SK, Hurst T, Holmes RS and Bellet AJD, Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem Pharmacol 40: 2641-2649, 1990.
56. Schmidt W and Chaney SG, Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53: 799-805, 1993.
57. Slater TF, Sawyer B and Strauli U, Studies on succinate-tetrazolium reductase systems III. Points of coupling of four different tetrazolium salts. Biochem Biophys Acta 77: 383-393, 1963.
58. Monner DA, An assay for growth of mouse bone marrow cells in microtiter liquid culture using the tetrazolium salt MTT, and its application to studies of myelopoiesis. Immunol Lett 19: 261-268, 1988.